Engineered Mesenchymal Stem Cells Expressing CD::UPRT and TRAIL Exhibit Potent Anti-Tumor Effects in Glioblastoma Patient-Derived Organoids
These findings validate the multifaceted anti-tumor activity of BM03 in GBOs that retain clinically relevant tumor heterogeneity and provide organoid-based preclinical evidence supporting further in vivo evaluation of BM03 as an MSC-based targeted therapeutic strategy for GBM.